Receptorska tirozinska proteinska kinaza erbB-2 (CD340, klaster diferencijacije 340, proto-onkogen Neu, Erbb2 (glodari), ili ERBB2 (ljudi)) protein je koji je kod ljudi kodiran ERBB2genom. Ona se često naziva HER2 (od енгл.human epidermal growth factor receptor 2) ili HER2/neu.
^Burstein HJ (2005). „The distinctive nature of HER2-positive breast cancers”. N. Engl. J. Med. 353 (16): 1652—4. PMID16236735. doi:10.1056/NEJMp058197.
^Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ (2002). „ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas”. The Journal of Biological Chemistry. 277 (25): 22692—8. PMID11950845. doi:10.1074/jbc.M201975200.
^Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, Garcia de Herreros A, Dunach M, Neckers LM (2001). „Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription”. Cancer Research. 61 (4): 1671—7. PMID11245482.
^Kanai Y, Ochiai A, Shibata T, Oyama T, Ushijima S, Akimoto S, Hirohashi S (1995). „c-erbB-2 gene product directly associates with beta-catenin and plakoglobin”. Biochemical and Biophysical Research Communications. 208 (3): 1067—72. PMID7702605. doi:10.1006/bbrc.1995.1443.
^Huang YZ, Won S, Ali DW, Wang Q, Tanowitz M, Du QS, Pelkey KA, Yang DJ, Xiong WC, Salter MW, Mei L (2000). „Regulation of neuregulin signaling by PSD-95 interacting with ErbB4 at CNS synapses”. Neuron. 26 (2): 443—55. PMID10839362. doi:10.1016/s0896-6273(00)81176-9.
^ абJaulin-Bastard F, Saito H, Le Bivic A, Ollendorff V, Marchetto S, Birnbaum D, Borg JP (2001). „The ERBB2/HER2 receptor differentially interacts with ERBIN and PICK1 PSD-95/DLG/ZO-1 domain proteins”. The Journal of Biological Chemistry. 276 (18): 15256—63. PMID11278603. doi:10.1074/jbc.M010032200.
^Bilder D, Birnbaum D, Borg JP, Bryant P, Huigbretse J, Jansen E, Kennedy MB, Labouesse M, Legouis R, Mechler B, Perrimon N, Petit M, Sinha P (2000). „Collective nomenclature for LAP proteins”. Nature Cell Biology. 2 (7): E114. doi:10.1038/35017119.
^Huang YZ, Zang M, Xiong WC, Luo Z, Mei L (2003). „Erbin suppresses the MAP kinase pathway”. The Journal of Biological Chemistry. 278 (2): 1108—14. PMID12379659. doi:10.1074/jbc.M205413200.
^Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, Neckers L (2001). „Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90”. The Journal of Biological Chemistry. 276 (5): 3702—8. PMID11071886. doi:10.1074/jbc.M006864200.
^Grant SL, Hammacher A, Douglas AM, Goss GA, Mansfield RK, Heath JK, Begley CG (2002). „An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells”. Oncogene. 21 (3): 460—74. PMID11821958. doi:10.1038/sj.onc.1205100.
^Li Y, Yu WH, Ren J, Chen W, Huang L, Kharbanda S, Loda M, Kufe D (2003). „Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein”. Molecular Cancer Research. 1 (10): 765—75. PMID12939402.
^Schroeder JA, Thompson MC, Gardner MM, Gendler SJ (2001). „Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland”. The Journal of Biological Chemistry. 276 (16): 13057—64. PMID11278868. doi:10.1074/jbc.M011248200.
^Wong L, Deb TB, Thompson SA, Wells A, Johnson GR (1999). „A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling”. The Journal of Biological Chemistry. 274 (13): 8900—9. PMID10085134. doi:10.1074/jbc.274.13.8900.
Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ (2003). „The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy”. The Oncologist. 8 (4): 307—25. PMID12897328. doi:10.1634/theoncologist.8-4-307.
Zhou BP, Hung MC (2003). „Dysregulation of cellular signaling by HER2/neu in breast cancer”. Seminars in Oncology. 30 (5 Suppl 16): 38—48. PMID14613025. doi:10.1053/j.seminoncol.2003.08.006.
Laudadio J, Quigley DI, Tubbs R, Wolff DJ (2007). „HER2 testing: a review of detection methodologies and their clinical performance”. Expert Review of Molecular Diagnostics. 7 (1): 53—64. PMID17187484. doi:10.1586/14737159.7.1.53.
Bianchi F, Tagliabue E, Ménard S, Campiglio M (2007). „Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections”. Cell Cycle. 6 (6): 643—6. PMID17374991. doi:10.4161/cc.6.6.4033.